Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers.Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 28, 2022 | Post-IPO Debt | €40M | 1 | European Investment Bank | — | Detail |
Apr 11, 2018 | Post-IPO Equity | $164M | — | — | — | Detail |
Jan 1, 2017 | Post-IPO Equity | — | 1 | — | — | Detail |
Apr 17, 2015 | IPO | — | — | — | — | Detail |
Jun 1, 2005 | Series C | €5.60M | 4 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
European Investment Bank | Yes | Post-IPO Debt |
4BIO Capital | — | Post-IPO Equity |
Andera Partners | — | Series C |
BankInvest Biomedical Venture | — | Series C |
Idinvest Partners | — | Series C |
ODYSSEE VENTURE | — | Series C |
Cellectis has acquired 2 organizations. Their most recent acquisition was Cyto Pulse Sciences on Sep 9, 2010. They acquired Cyto Pulse Sciences for $2.20M.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Sep 9, 2010
Cyto Pulse Sciences
|
Health Care | acquisition | $ 2.20M | Detail |
Sep 15, 2011
Cellartis
|
Biotechnology | acquisition | — | Detail |